About Treeline Biosciences
Treeline Biosciences is a clinical-stage biopharmaceutical company building transformative precision medicines for patients with cancer and other serious conditions. The company prioritizes molecular targets in oncology that are validated but difficult to drug, using an integrated drug discovery platform spanning mechanistic biology, medicinal chemistry, computational science, and structural biology. Its pipeline includes three Phase 1 oncology programs (TLN-121, TLN-254, TLN-372) and a fourth nearing clinical entry.
Company details
Funding
Total raised
$1.1B
Last stage
Series A
Investors
Founders
Josh Bilenker
Former founder and CEO of Loxo Oncology, which was acquired by Eli Lilly for ~$8 billion in 2019. Earlier roles include venture capital and Medical Officer at the FDA's Office of Oncology Drug Products.
LinkedInJeff Engelman
Former Global Head of Oncology at the Novartis Institutes for BioMedical Research and prior Director of Thoracic Oncology at Massachusetts General Hospital.
Jeffrey Engelman
Medical oncologist and former Global Head of Oncology at Novartis Institutes for BioMedical Research. Prior to industry, led an academic research lab and served as Director of Molecular Therapeutics and Thoracic Oncology at Massachusetts General Hospital.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.